206
Participants
Start Date
November 2, 2016
Primary Completion Date
March 27, 2020
Study Completion Date
March 27, 2020
Enzalutamide
Oral Capsule
Flutamide
Oral tablet
Androgen deprivation therapy
All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
Site JP00024, Nagoya
Site JP00025, Nagoya
Site JP00038, Matsuyama
Site JP00051, Iizuka
Site JP00045, Isesaki
Site JP00005, Maebashi
Site JP00043, Ōta
Site JP00054, Hakodate
Site JP00001, Sapporo
Site JP00002, Sapporo
Site JP00048, Sapporo
Site JP00055, Mito
Site JP00019, Sagamihara
Site JP00020, Yokohama
Site JP00021, Yokohama
Site JP00044, Yokosuka
Site JP00046, Kashihara
Site JP00033, Kurashiki
Site JP00028, Hirakata
Site JP00030, Sayama
Site JP00027, Suita
Site JP00009, Kitaadachi-gun
Site JP00022, Hamamatsu
Site JP00049, Utsunomiya
Site JP00011, Bunkyo-ku
Site JP00017, Bunkyo-ku
Site JP00013, Koto-ku
Site JP00014, Nakano-ku
Site JP00016, Shinagawa-ku
Site JP00018, Shinjuku-ku
Site JP00034, Ube
Site JP00010, Chiba
Site JP00053, Chiba
Site JP00039, Fukuoka
Site JP00040, Fukuoka
Site JP00050, Fukuoka
Site JP00035, Hiroshima
Site JP00026, Kyoto
Site JP00006, Nagano
Site JP00008, Nagano
Site JP00041, Nagasaki
Site JP00029, Osaka
Site JP00031, Osaka
Site JP00032, Osaka
Site JP00042, Saga
Site JP00037, Tokushima
Site JP00052, Toyama
Lead Sponsor
Collaborators (1)
Pfizer
INDUSTRY
Astellas Pharma Inc
INDUSTRY